Introduction
Toll-like receptors (TLR) on the surface of cells of the respiratory tract play an essential role in sensing the presence of microorganisms in the airways and lungs. These receptors trigger inflammatory responses, activate innate immune responses, and prime adaptive immune responses to eradicate invading microbes [1] . TLR are members of a family of pattern-recognition receptors, which recognize molecular structures of bacteria, viruses, fungi and protozoa (pathogen-associated molecular patterns or PAMPs), as well as endogenous structures and proteins re1eased during inflammation (damage/danger-assoeiated molecular patterns or DAMPs). To date, ten different TLR have been identified in humans and twelve in mice. TLR are expressed on all cells of the immune system, but also on parenchymal cells of many organs and tissues. The bin ding of a PAMP to a TLR results in cellular activation and initiates a variety of effector functions, inc1uding cytokine secretion, proliferation, co-stimulation or phagocyte maturation. To faeilitate microbial recognition and to amplify cellular responses, certain TLR require additional proteins, such as lipopolysaccharide (LPS) bin ding protein (LBP), CD14, CD36 and high mobility group box-I protein (HMGB-l). In this chapter, the role of CD14 as an accessory receptor for TLR in lung inflammation and infection is discussed. The central role of CD14 in the recognition ofvarious PAMPs and amplification ofimmune and inflammatory responses in the lung is depicted in Figure 1 .
CD14 was characterized as a receptor for bacterial endotoxin (LPS) in 1990, alm ost a decade before the discovery and characterization of TLR, and can be regarded as the first described pattern-recognition receptor [2] . The protein was first identified as a differentiation marker on the surface of monocytes and macrophages and was designated CD14 at the first leukocyte typing workshop in Paris in 1982. The genomic DNA of human CD14 was cloned in 1988 and the gene was later mapped to chromosome 5q23 -31. Several polymorphisms have been found in the CD14 gene, of which nuc1eotide polymorphisms at position -159 and -1619 correlated with decreased lung function in endotoxin-exposed farmers [3] .
The CD14 gene consists of two exons which code for a single mRNA that is translated into a protein of 375 amino acids. The CD14 protein is composed of eleven leuein-rich repeats, which are also found in TLR and which are important in PAMP bin ding. Moreover, the crystal structure of CD14 revealed that the protein has a 'horse-shoe' shape, similar to TLR4, and that LPS is bound within the pocket [4] . In contrast to TLR, however, CD14 lacks a transmembrane domain, and thus cannot initiate intracellular signal transduction by itself. The CD14 protein is processed in the endoplasmatic reticulum and expressed as a 55 kDa glycoprotein on the cell sur- , which lacks an intracellular domain for signal transduction, is expressed on the surface of alveolar macrophages, infiltrating monocytes and neutrophils, and at lower levels also on epithelial and endothelial cells in the lung. C014 recognizes and binds various structures from invading microbes, such as Iipopolysaccharide (LPS) from Gram-negative bacteria, Iipoteichoic acid (LTA) from Grampositive bacteria, Iipoarabinomannan (LAM) from mycobacteria, viral double stranded (ds) RNA and F glycoprotein (F-gp) from respiratory syncytial virus (RSV). C014 subsequently transfers these bound cornponents to TolI-like receptors (TLR) which than trigger cell activation. Binding of LPS to C014 is regulated by additional accessory receptors in the lung, including LPS-binding protein (LBP) and a number of surfactant proteins (SP). Furthermore, soluble C014 (sC014) enhances LPS-induced activation of cells with low C014 expression. Depending on the microbe and the PAMPs it expresses, C014-amplified responses can either be beneficial to the hostby induction of an adequate inflammatory and immune response to eradicate the invading microbe, or detrimental to the host by excessive inflammation and/or dissemination of the pathogen.
face via a glycosylphosphatidyl (GPI) anchor [5] . Like other GPI-anchored proteins, CD14 accumulates on the cell surface in microdomains known as lipid rafts , which are fairly rieh in cholesterol and accumulate several kinases at the intracellular site. CD14 is expressed predominantly on the surface of 'myeloid' cells, such as monocytes, macrophages and neutrophils, but at lower levels also on epithelial cells, endothelial cells and fibroblasts.
In addition to being expressed as a GPI-anchored membrane protein, CD14 is also expressed in a soluble form (sCDI4) [2] . sCD14 may result from secretion ofthe protein before coupling to the GPI an chor or from shedding or cleavage from the surface of monocytes. sCD14 is present in the circulation and other body fluids and levels of sCD14 in plasma increase during inflammation and infection. Since inter-leukin (IL)-6 induces sCD14 expression in liver cells it is regarded as an acute phase protein. In bronchoalveolar lavage (BAL) fluid from patients with acute respiratory distress syndrome (ARDS), sCD14 levels were strongly increased and corre1ated with total protein levels and neutrophil numbers in the BAL fluid [6] , suggesting that sCD14 contributes to the inflammatory process in the lung.
CD14 is a molecule with a wide range of functions. In addition to functioning as a pattern recognition receptor for a variety of microbialligands, CD14 also acts as a receptor for endogenous molecules like intercellular adhesion molecule (ICAM)-3 on the surface of apoptotic cells, amyloid peptid, ceramide, and urate crystals. Ligation of CD14 by these ligands, except for apoptotic cells, mediates activation of inflammatory responses.
C014 and the LPS Receptor Complex
LPS is the major constituent of the outer membrane of Gram-negative bacteria and is one of the most potent TLR ligands. CD14 together with LBP plays an essential role in binding of LPS to the TLR4/MD-2 complex [7) . LBP, which, among others, is present in the bloodstream and BAL fluid [8] , binds to LPS aggregates and transfers LPS monomers to CD14. CD14 associates with TLR4/MD-2 and transfers the LPS monomer to this complex [7] . Likewise, sCD14 is able to mediate LPS-activation of cells with low membrane CD14 expression, such as epithelial and endothelial cells [9] . However, at high concentrations, LBP and sCD14 are also able to downregulate LPS-induced responses by transfer of LPS to lipoproteins for subsequent removal [10] . Recent data indicate that LPS is bound by MD-2 within the TLR4/MD-2 complex [11] and that subsequent conformational changes in TLR4 lead to reorganization of its cytoplasmic domain, enabling the recruitment of the adaptor proteins, myeloid differentiation primary-response protein 88 (MyD88) and TIR-domain-containing-adaptor-protein-inducing-interferon (IFN)-ß (TRIF) [12] . These adaptors initiate signal transduction to the nucleus by activation of nuclear factor (NF)-KB and IFN regulatory transcription factor (IRF)-3, leading to the production of cytokines that regulate inflammatory cells [12] . In macrophages, TRIF-dependent signaling is essential for the expression of the majority of LPS-induced genes, including IFN-a/ß· Recently, it was reported that, in the absence of CD14, the TLR4/MD-2 complex can distinguish between different chemotypes of LPS [13] . Smooth LPS is synthesized by most Gram-negative bacteria and consists of three modules: The lipid A moiety, a core polysaccharide, and an O-polysaccharide of variable length (made up of 1 to over 50 monosaccharide units) [7] . Gram -negative bacteria that fail to add the core polysaccharide or the O-polysaccharide chain to the lipid A moiety produce 'rough' LPS, named after the rough morphology of the colonies these bacteria form. Lipid A, the bioactive part of both smooth and rough LPS, is responsible for most of the pathogenic effects in Gram-negative bacterial infections [7, 12] . Murine macrophages lacking CD14 secreted equal amounts of tumor necrosis factor-u (TNF) to macrophages expressing CD14 upon stimulation with rough LPS, but failed to secrete TNF in response to smooth LPS, an effect which was reversed by addition of sCD14 [13] . Moreover, macrophages lacking CD14 failed to secrete IFN-a/ß in response to either rough or smooth LPS. These findings indicate that CD14 is required for activation of the TLR4/TRIF pathway by either smooth or rough LPS, and required for the activation of TLR4/MyD88 pathway by smooth but not by
IV
A. Anas, T. van der Poil, and A.F. de Vos rough LPS [13] . In addition to LPS, CD14 also facilitates TLR4 activat ion by other PAMPs including certain viral components [13, 14] .
In the lung, binding of LPS to TLR4 is influenced by a number of surfactant proteins (SP), including SP-A, SP-C and SP-D [15] . These surfactants are able to influence the interaction between TLR4 and LPS by direct binding to LPS; i.e., SP-A binds to rough LPS and lipid A, but no t to smooth LPS, SP-C also binds to rough LPS, and SP-D binds to both rough and smooth LPS. SP-A and SP-C binding to LPS inhibits TNF secretion by alveolar mac rophages, whereas SP-D binding to LPS moderately enhances TNF secretion by alveolar macrophages. In addition, SP-A, SP-C and SP-D also bind to CD14 at the site which recognizes LPS. Strikingly, binding of SP-A to CD14 enhanced the binding of rough LPS and binding of SP-C to CD14 augmented binding of smooth LPS [15] , whereas binding of SP-A to CD14 reduced binding of smooth LPS and binding of SP-D to CD14 decreased binding of both smooth and rough LPS. Furthermore, SP-D influences LPS-induced TNF secretion by alveolar macrophages by regulating matrix metalloproteinase-mediated cleavage of CD14 from the surface of these cells [16] .
Together, these findings suggest that LPS recognition in the lung and subsequent induction of inflammatory immune response is a complexly regulated process.
(014 and other Pattern Recognition Receptors
In addition to LPS-induced activation of TLR4, CD14 also amplifies a number of TLR-dependent responses triggered by other bacterial PAMPs, including peptidoglycan, lipoteichoic acid (LTA) and lipoarabinomannan (LAM) [17 -19] .
Peptidoglycan is an essential cell wall component of virtually all bacteria. Peptidoglycan is a polymer of N-acetylglucosamine and N-acetylmuramie acid, crosslinked by short peptides. Breakdown products of peptidoglycan are recognized by different classes ofpattern-recognition receptors [19] . Polymerie soluble peptidoglycan is recognized by TLR2 on the surface of cells, and the interaction of peptidoglycan with TLR2 triggers MyD88-dependent activation and nuclear translocation of NF-KB, and subsequently the transcription and secretion of cytokines. Muramyl dipeptide and y-D-glutamyl-meso-diaminopimelic acid , which are Iow-rnolecular weight breakdown fragments of peptidoglycan, are recognized by intracellular pathogen recognition receptors, nucleotide-binding oligomerization domain containing (Nod)2 and Nod l , respectively [19] . Ligand binding to these receptors triggers interaction with the receptor-interacting pro tein kinase, RIP2, which activates NF-KB. Of these peptidoglycan breakdown products, only polymerie peptidoglycan binds to CD14, and CD14 enhances polymerie peptidoglycan-induced TLR2 activation. The low molecular weight fragments of peptidoglycan, like muramyl dipeptide, do not bind to CD14, do not induce cell activation through CD14 and also do not interfere with the binding ofpolymerie peptidoglycan to CD14 [19] . Furthermore, unlike LPS, peptidoglycan bound to sCD14 is not able to activate epithelial and endothelial cells with low membrane CD14 expression.
LTA is a constituent of the cell wall of Gram-positive bacteria, anchored on the outer face of the cytoplasmie membrane and commonly released during growth and antibiotic therapy. Like polymerie peptidoglycan, LTA induces NF-KB activation and cytokine secretion in a TLR2-dependent manner. LTA is recognized by LBP and CDI4, and these accessory receptors both enhance LTA-induced cell activation [18] . Presumably in a similar manner, CD14 also enhances TLR2-dependent cellular acti-vation by LAM derived from the cell-wall of mycobacteria. LAM derived from slowly growing virulent mycobacteria like Myeobacterium tuberculosis and M. leprae is capped with mannose (ManLAM), whereas LAM from avirulent and fast growing mycobacterial species is uncapped (AraLAM). Strikingly, AraLAM from avirulent mycobacteria is much more potent in inducing TNF secretion by macrophages than ManLAM from virulent mycobacterial strains [12] . AraLAM -, but not ManLAMinduced TNF secretion by monocytes and macrophages was largely CDI4-, TLR2-and MyD88-dependent [17] .
Recently CD14 was also found to enhance the innate immune response triggered by the TLR3 ligand poly(I:C), a synthetic mimic of double stranded RNA [20] . TLR3 together with TLR7 and TLR8 are regarded as sensors for viral infection, since these IV receptors recognize viral nudeic acids, like single and double stranded RNA. The potentiating effect of CD14 on TLR3 activation resulted from increased uptake of poly(I:C) and intracellular delivery to the compartment where TLR3 resides [20] . Taken together, these findings suggest that CD14 plays an important role in the induction and amplification of inflammatory responses evoked by a wide variety of pathogens.
Role of (D14 in LPS-and LTA-induced Lung Inflammation
The contribution of CD14 to TLR ligand-induced lung inflammation has been investigated in several animal studies (l able 1) . Intratracheal administration of LPS did not significantly induce TNF release and neutrophil accumulation in the lungs of rabbits, unless LPS was complexed with LBP [21] or the animals were subjected to mechanical ventilation [22] . Intratracheal instillation of anti-CDl4 antibodies together with LPS/LBP or intravenous pretreatment with anti-CD 14 or anti-TLR4 antibodies before mechanical ventilation markedly reduced these inflammatory responses [21, 22] . Despite a reduction in lung neutrophil number, intravenous anti-CD14 treatment of rabbits exposed to LPS and subjected to ventilation did not cause a decrease in lung chemokines, induding CXCL8 (IL-8), growth related oncogene (GRO) and monocyte chemoattractant protein (MCP)-I , whereas anti-TLR4 treatment did lower the level of GRO moderately and of CXCL8 significantly [22] . These finding s reveal that LPS alone does not cause significant lung inflammation in rabbits and suggest that additional accessory signals are required. Whether mechanical ventilation induces increased release of LBP or release of (endogenous) DAMPs which potentiate the LPS-induced response remains to be determined.
In contrast to rabbits, administration of LPS alone to lungs of naive mice induced severe pneumonitis, irrespective of the manner of LPS delivery (inhalation or intratracheal or intranasal instillation) or the source of LPS (Eseheriehia eoli or Acinetobaeter baumannii). Using antibody-treated and gene-deficient mice, CD14 was found to be critically involved in the development of LPS-induced lung inflammation [23] [24] [25] [26] . A study with CDl4-deficient mice and TLR4 mutant mice (lacking a functional TLR4) showed that LPS-induced vascular leakage, neutrophil infiltration, nuc1ear translocation ofNF-KB. The release of cytokines (TNF and IL-6) and chemokin es (CXCLl and CXCL2) in the lung was completely dependent on these pattern recognition receptors [24] . Similar observations were made by others using mice treated intravenously with anti-CDl4 antibodies [23] and by our group using CDI4-deficient and TLR4-deficient mice [25] . Furthermore, intratracheal treatment of CD14-deficient mice with sCD14 restored the inflammatory response to the level present in wild-type mice, whereas treatment with wild-type alveolar macrophages restored the neutrophil infiltration of the lung but not pulmonary TNF release [26] . Moreover, treatment with wild-type alveolar macrophages also restored neutrophil infiltration in the lung of LPS-exposed TLR4-defident mice [27] . These findings indicate that sCD14, and CD14 and TLR4 on the surface of alveolar macrophages contribute to the development of LPS-induced lung inflammation. However, when a high dose of LPS was administered to the lungs of mice, acute lung inflammation was absent in mice lacking functional TLR4, but only partially reduced in CD14 deficient mice [24] . Thus, LPS-induced lung inflammation is entirely dependent on TLR4 and, depending on the dose of LPS, also on the presence of CD14 in the lung.
Our group determined whether CD14 also contributes to the development oflung inflammation induced by LTA, a TLR2 ligand from the cell wall of Gram-positive bacteria [28, 29] . Lung inflammation induced by Staphylococcus aureus LTA was completely dependent on TLR2, but independent of LBP and only moderately dependent on CD14 expression. As compared to wild-type mice, S. aureus LTAinduced neutrophil influx was unchanged in CDl4-deficient mice, whereas TNF and CXCL2 release in the lung were partially reduced [28) . Strikingly, however, pulmonary inflammation was also greatly diminished in TLR4-deficient mice, as well as in mice deficient for platelet act ivating factor receptor (PAFR), a known receptor for LTA on epithelial cells. Similarly, lung inflammation induced by Streptococcus pneumoniae LTA, which is less potent compared S. aureus LTA, was also completely dependent on TLR2 expression. However, in contrast to S. aureus LTA, neutrophil infiltration of the lung was moderately reduced in CDl4-deficent mice treated with pneumococcal LTA, whereas TNF and CXCL2 release in the lung was unchanged IV [29) . Moreover, pneumococcal LTA-induced lung inflammation was moderately diminished in TLR4-deficient mice. Thus, despite the amplifying effect on LTAinduced TLR2-mediated responses in vitro, CD14 contributes minimally to lung inflamm ation induced by LTA. The unexpected contribution of TLR4 to LTA-induced lung inflammation may result from DAMPs generated during the inflammatory process in the respiratory tract.
Role of (014 in Lung Infection
In line with the findings that CD14 contributes to LPS-induced lung inflammation in mice, a number of studies have shown that CD14 is essential for the host defense response in the lung against Gram-negative bacteria, such as nontypeable Haemophilus influenzae, a possible cause of community acquired pneumonia, and A . baumannii and E. coli, which are frequent inducers of nosocomial pneumonia (l abte 1). Nontypeable H . influenzae expresses the TLR4 ligands LPS and lipooligosaccharide on its cell wall, as well as several TLR2 ligands, including lipoproteins and porins. Previously, we found that activation of alveolar macrophages by nontypeable H. influenzae depended on expression ofTLR4, TLR2, and CD14 [30] . Moreover, bacterial clearance after intranasal infection with nontypeable H. influenzae was markedly reduced in CDl4-deficient and TLR4-deficient mice, as well as in TLR2-deficient mice at later stages of the disease [30] . Interestingly, despite impaired bacterial clearance in CDl4-deficient and TLR4-deficient mice, the inflammatory response in the lung was strongly reduced in TLR4 deficient mice, but elevated in CD14 deficient mice. Similar observations were made with encapsulated H. influenzae in TLR4-mutant mice [31] . Furthermore, clearance of nontypeable H. influenzae was also significantly impaired in MyD88-deficient mice, but not in mice lacking functional TRIF [30] . In a similar manner, CD14 was involved in the host defense response against A. baumanii [25] . CDl4-deficient mice, like-TLR4-deficient mice, suffered from impaired bacterial clearance in the lungs and enhanced bacterial dissemination after intranasal infection with A. baumannii. However, unlike TLR4-deficient mice, CDl4-deficient mice developed similar inflammatory responses compared to wild-type mice . These findings suggest a role for CD14 in anti-bacterial responses against nontypeable H. influenzae and A. baumannii. Although the role of TLR4 (and TLR2) in phagocytic killing is controversial, it is unknown whether CD14 is involved in such processes. The role of CD14 in E. coli-induced pneumonia was determined in anti-CDl4 antibody treated rabbits. Intravenous anti-CD14 antibody treatment of rabbits inoculated with E. coli by bronchial instillation, resulted in decreased bacterial clearance from the lungs, but had no effect on neutrophil infiltration or cytokine release in the lungs [32] . However, anti-CDl4 treatment pro-IV A. Anas, T. van der Poil, and A.F. de Vos tected against sustained hypotension and reduced the levels of nitrate and nitrite in the blood. The contribution of CD14 to E. coli-induced pneumonia has not been investigated in mice, whereas the role of the other components of the LPS receptor complex (TLR4, MD-2, MyD88, TRIF) has been determined using gene-deficient or mutant mice. Although analysis of bacterial c1earance after intranasal infection of TLR4-mutant mice with E. coli produced inconsistent results [33] , lack of MD-2 or TRIF resulted in impaired bacterial c1earance after E. coli instillation in the lungs [34, 35] . Moreover, E. coli-induced neutrophil accumulation and cytokine release was significantly reduced in mice devoid of functional TLR4, MD-2, MyD88 or TRIF [33] [34] [35] . These findings indicate that signaling through the TLR4 receptor complex is essential in the host defense response against E. coli, and suggests that CD14 may contribute to these E. coli-induced responses.
To our knowledge, it is unclear whether CD14 contributes to host defense against Pseudomonas aeruginosa, a frequent cause of nosocomial pneumonia, and Burkholderia cepacia, aprevalent Gram-negative bacterium, together with P. aeruginosa, in patients with cystic fibrosis. Recently, it was found that both TLR4 and TLR5 are critical in the host response to P. aeruginosa and that TLR4-deficient mice were not susceptible to intratracheal P. aeruginosa infection unless a bacterial mutant devoid of flagellin production was used [36] . A similar approach is required to determine a role for CD14 in Pseudomonas-induced pneumonia. It is plausible that CD14 also contributes to the host response against B. cepacia, since LPS from this bacterium signals through TLR4 and anti-CD14 antibodies dramatically inhibited B. cepaciainduced chemokine secretion by lung epithelial cells [37] . Whether CD14 contributes to host defense response against Klebsiella pneumoniae, a known cause of nosocomial pneumonia, also remains to be determined, but data from our study with TLR4-mutant mice indicate that signaling through TLR4 is essential for successful clearance of this bacterium [38] .
In contrast to the essential role of pulmonary TLR4 and CD14 in the host defense response against most Gram-negative bacteria, we found that TLR4 was not involved and CD14 played a remarkable detrimental role in the host response to B. pseudomallei, the causative organism of melioidosis (the most common cause of community-acquired sepsis in Southeast Asia) [39, 40] . CD14-deficient mice infected intranasally with B. pseudomallei were protected from mortality, accompanied by enhanced bacterial c1earance in the lung, blood and liver, and reduced cellular infiltration in the lung [39] , whereas the course of disease in TLR4-deficient mice was indistinguishable from wild-type mice [40] . Moreover, intranasal administration of sCD14 to CD14-deficient mice partially reversed the phenotype into that of wildtype mice [40] . Interestingly, these findings in B. pseudomallei-infected CD14-deficient mice strongly resemble our previous results found with TLR2-deficient mice, and are in line with the observation that B. pseudomallei expresses an atypical LPS which signals through TLR2 [39] . Whether CD14 interacts with TLR2 in B. pseudomallei-induced responses, and by which mechanism these receptors facilitate the growth and dissemination of B. pseudomallei after intranasal infection remains to be determined.
In the model for S. pneumoniae-induced pneumonia, we observed an unexpected detrimental role for CD14 in the innate host defense response. S. pneumoniae, a Gram-positive bacterium and the single most frequent pathogen causing community-acquired pneumonia, induces severe lung inflammation and sepsis in wild-type mice after intranasal instillation. Strikingly, CD14-deficient mice were protected against pneumococcal pneumonia, presumably as a result of reduced bacterial spread to the circulation and reduced lung inflammation [41] . In contrast, TLR2-deficient and TLR4-mutant mice were not protected against pneumococcal pneumonia [38, 42] , but in fact TLR2 seemed redundant for efficient bacterial clearance and TLR4-mutant mice were more susceptible to pneumonia, accompanied by impaired bacterial clearance. However, as in CDl4-deficient mice, lung inflammation was also reduced in pneumococci-infected TLR2-deficient mice [42] . Since intrapulmonary treatment with sCD14 rendered CDl4-deficient mice equally susceptible to S. pneumoniae as wild-type mice [41] , these results suggest that S. pneumoniae abuses (s)CDI4 in the lung to cause invasive respiratory tract infection. Interestingly, the phenotype of CD14 deficient mice strongly resembled the phenotype of mice deficient for PAFR [43] , a receptor for phosphoryl choline from the pneumococcal cell wall which facilitates pneumococcal invasion of cells. Further studies are required to determine whether CD14 serves as a chaperone in the presentation of S. pneumoniae to the PAFR so that the phosphoryl-PAFR-mediated invasion is facilitated.
Since M. tuberculosis expresses a number of molecules, such as lipoproteins, which activate immune cells in a CDl4-dependent manner, we and others investigated whether CD14 also contributed to the host immune response in mice with lung tuberculosis [44] . Although initially after intranasal infection of wild-type and CDl4-deficient mice no differences in bacterial loads, cell infiltration and release of most cytokines in the lung were found [44, 45] , at later time points (> 20 weeks after infection) CDl4-deficient mice were protected from mortality presumably as a result of a reduced inflammatory response in the lungs [44] . These findings are completely opposite to the results from M. tuberculosis-infected TLR2-deficient and TLR4-mutant mice, which suffered from reduced bacterial clearance, chronic inflammation, increased cellular infiltration of the lungs and reduced survival [46] [47] [48] . The mechanism underlying the detrimental effect of CD14 in the host response against M. tuberculosis remains to be established.
In addition to its role in (myco)bacterial infections, CD14 may also playa role in the pulmonary host response against respiratory syncytial virus (RSV), the most common cause of lower respiratory tract disease in infants and young children worldwide, and influenza A virus, a cause of pneumonia in very young children, the elderly and immunocompromised patients. The envelop F glycoprotein from RSV and certain influenza A virus components activate macrophages in a CDI4-dependent manner [14, 20] . Experiments with wild-type and TLR4-mutant mice infected intranasally with RSV showed that viral clearance was reduced in the absence of functional TLR4 [14] , due to impaired natural killer (NK) cell migration and function and impaired cytokine secretion. Recently, it was found that TLR2 and TLR6 are also involved in recognition of RSV [49] . Whether CD14 contributes to these TLR-mediated immune responses against RSV remains to be determined. Using CDl4-deficient mice, we demonstrated that CD14 played a minimal role in influenza A virus-induced pneumonia [50] . During the entire course of disease, viral loads were slightly reduced in CD14-deficient mice, but this did not result from improved lymphocyte recruitment or lymphocyte activation, or consistent changes in pulmonary cytokines [50] . Thus, despite the fact that influenza A expresses ligands that require CD14 for immune cell activation [20] , CD14 seems redundant in the host defense reponse against influenza A virus.
Conclusion
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CD14 plays a central role in the lung in the recognition and binding of a var iety of {myco}bacterial and viral components, and in the amplification of subsequent host responses. The studies discussed in this chapter indicate that the contribution of CD14 to the pulmonary host defense responses may range from beneficial to detrimental, depending on the microbe and the PAMPs it expresses. Interfering with CDI4-LPS or CDI4-LTA interactions reduced lung inflammation. Interference with CDl4-pathogen interactions, however, did not have a significant effect on M. tuberculosis or influen za A virus infection, resulted in reduced c1earance of nontypeable H. influenzae, E. coli or A. baumannii in the lung, but enhanced c1earance {and reduced dissemination} of B. pseudomallei or S. pneumoniae. The latter observation indicates that certain pathogens may abuse CD14 in the lung to cause invasive disease. Whether CD14 is a suitable target for intervention in these latter infectious diseases and/or in aberrant inflammatory responses during pneumonia requires further study.
